Switching - null sWR [RSABE / ABEL]

posted by d_labes  – Berlin, Germany, 2010-05-04 16:04 (5886 d 09:12 ago) – Posting: # 5284
Views: 41,632

Dear Dave, dear All,

❝ One thing I was happy about with the FDA progesterone recommendations was that the FDA specified 0.294 for sig_wr, because a few of their previous publications recommended using 0.25, which didn't map close to the 30% intraCV cutoff.


Please note sigmaS=0.294 is only the switching variability i.e. from which on the scaled ABE criterion is allowed if sWR>sigmaS. In their SAS code the regulatory constant s0 is still 0.25.
See f.i. on page 6 and 8 of the progesterone draft guidance:
  theta=((log(1.25)/0.25)**2
(=0.89257422)

This leads to the discontinuity at CV=30% and the inflation of the consumer's risk around CV=30% as described by:
L. Endrenyi and L. Tothfalusi
"Regulatory Conditions for the Determination of Bioequivalence of Highly Variable Drugs"
J. Pharm. Pharmaceut. Sci. (www.cspsCanada.org) 12 (1): 138 - 149, 2009


Edit: online resource added. [Helmut]

Regards,

Detlew

Complete thread:

UA Flag
Activity
 Admin contact
23,654 posts in 4,992 threads, 1,571 registered users;
136 visitors (0 registered, 136 guests [including 20 identified bots]).
Forum time: 01:16 CEST (Europe/Vienna)

The idea is to try and give all the information to help others
to judge the value of your contribution;
not just the information that leads to judgment
in one particular direction or another.    Richard Feynman

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5